JP2006515370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006515370A5 JP2006515370A5 JP2006500641A JP2006500641A JP2006515370A5 JP 2006515370 A5 JP2006515370 A5 JP 2006515370A5 JP 2006500641 A JP2006500641 A JP 2006500641A JP 2006500641 A JP2006500641 A JP 2006500641A JP 2006515370 A5 JP2006515370 A5 JP 2006515370A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- pharmaceutical composition
- neurotrophin
- benzylaminosalicylic
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- RVIOLHZEGBIJDK-UHFFFAOYSA-N 2-(benzylamino)oxybenzoic acid Chemical group OC(=O)C1=CC=CC=C1ONCC1=CC=CC=C1 RVIOLHZEGBIJDK-UHFFFAOYSA-N 0.000 claims 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 6
- HABROHXUHNHQMY-UHFFFAOYSA-N 2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C(=C(F)C(=C(F)C=2F)C(F)(F)F)F)=C1 HABROHXUHNHQMY-UHFFFAOYSA-N 0.000 claims 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 4
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- JSJGDVGFCIWRKT-UHFFFAOYSA-N 2-aminooxy-5-[[4-(trifluoromethyl)phenyl]methyl]benzoic acid Chemical compound C1=C(C(O)=O)C(ON)=CC=C1CC1=CC=C(C(F)(F)F)C=C1 JSJGDVGFCIWRKT-UHFFFAOYSA-N 0.000 claims 2
- LNDYNJBZIIMHKN-UHFFFAOYSA-N 2-hydroxy-5-[(4-methoxyphenyl)methylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC1=CC=C(O)C(C(O)=O)=C1 LNDYNJBZIIMHKN-UHFFFAOYSA-N 0.000 claims 2
- MEOMKGGNUSFYCD-UHFFFAOYSA-N 2-hydroxy-5-[(4-nitrophenyl)methylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 MEOMKGGNUSFYCD-UHFFFAOYSA-N 0.000 claims 2
- UGCLFNDSMFHCBO-UHFFFAOYSA-N 5-(benzylamino)-2-hydroxybenzoic acid Chemical group C1=C(O)C(C(=O)O)=CC(NCC=2C=CC=CC=2)=C1 UGCLFNDSMFHCBO-UHFFFAOYSA-N 0.000 claims 2
- LOHHDUQMXAYMSQ-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(Cl)=CC=2)=C1 LOHHDUQMXAYMSQ-UHFFFAOYSA-N 0.000 claims 2
- YWRQYUUZJRYBKN-UHFFFAOYSA-N 5-[(4-fluorophenyl)methylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(F)=CC=2)=C1 YWRQYUUZJRYBKN-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 2
- 102000004230 Neurotrophin 3 Human genes 0.000 claims 2
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 2
- 102100033857 Neurotrophin-4 Human genes 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010038848 Retinal detachment Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000001146 hypoxic effect Effects 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 229940032018 neurotrophin 3 Drugs 0.000 claims 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000004264 retinal detachment Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-0003765 | 2003-01-20 | ||
| KR10-2003-0003765A KR100522188B1 (ko) | 2003-01-20 | 2003-01-20 | 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법 |
| PCT/KR2004/000119 WO2004064844A1 (en) | 2003-01-20 | 2004-01-20 | Method for inhibition of necrosis induced by neurotrophin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006515370A JP2006515370A (ja) | 2006-05-25 |
| JP2006515370A6 JP2006515370A6 (ja) | 2006-08-17 |
| JP2006515370A5 true JP2006515370A5 (enExample) | 2007-03-08 |
Family
ID=36081148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006500641A Pending JP2006515370A (ja) | 2003-01-20 | 2004-01-20 | ニューロトロフィンによって誘導される細胞壊死の抑制方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7608585B2 (enExample) |
| EP (1) | EP1592429A4 (enExample) |
| JP (1) | JP2006515370A (enExample) |
| KR (1) | KR100522188B1 (enExample) |
| CN (1) | CN1738627A (enExample) |
| AU (1) | AU2004206187A1 (enExample) |
| CA (1) | CA2518888A1 (enExample) |
| WO (1) | WO2004064844A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8241622B2 (en) | 2001-07-13 | 2012-08-14 | University Of Iowa Research Foundation | Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
| DK1551793T3 (en) * | 2002-06-19 | 2016-04-25 | Gnt Pharma Co Ltd | Tetrafluorobenzyl derivatives and pharmaceutical compositions containing these for the prevention and treatment of acute and chronic neurodegenerative diseases of the central nervous system |
| KR20060121721A (ko) * | 2005-05-23 | 2006-11-29 | 주식회사 중외제약 | 테트라플루오로벤질 유도체 또는 그의 염을 함유하는주사제용 조성물 |
| EP1883619B8 (en) | 2005-05-25 | 2013-05-01 | JW Pharmaceutical Corporation | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
| JP5208369B2 (ja) * | 2005-08-24 | 2013-06-12 | ニューロテック ファーマシューティカルズ カンパニー リミテッド | 神経細胞の死滅または神経機能の障害を治療するための薬学製剤及び併用療法 |
| JP2009521928A (ja) | 2005-12-30 | 2009-06-11 | ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン | 神経細胞変性疾患の治療に有用な化合物を特定する方法 |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| KR100852962B1 (ko) * | 2007-11-12 | 2008-08-20 | 주식회사 뉴로테크 | 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법 |
| KR101204108B1 (ko) * | 2009-02-09 | 2012-11-22 | 주식회사 지엔티파마 | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 |
| EP2417972B1 (en) * | 2009-04-06 | 2017-06-14 | Neurotech Pharmaceuticals Co., Ltd. | Pharmaceutical composition for treating or preventing burn injuries |
| US11702672B2 (en) | 2016-02-08 | 2023-07-18 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
| US11684679B2 (en) | 2016-03-07 | 2023-06-27 | University Of Iowa Research Foundation | AAV-mediated expression using a synthetic promoter and enhancer |
| US12173305B2 (en) | 2016-05-26 | 2024-12-24 | University Of Iowa Research Foundation | cis and trans requirements for terminal resolution of human bocavirus 1 |
| WO2018132747A1 (en) | 2017-01-13 | 2018-07-19 | University Of Iowa Research Foundation | Bocaparvovirus small noncoding rna and uses thereof |
| CA3082573A1 (en) * | 2017-11-15 | 2019-05-23 | Vanderbilt University | Methods and compositions for the improvement of lysosomal function and treatment of neurodegenerative disease |
| CN110257392A (zh) * | 2019-06-28 | 2019-09-20 | 西安医学院 | 转录后水平低氧调控基因、应用及其调控方法 |
| CA3174709A1 (en) * | 2020-03-11 | 2021-09-16 | Gnt Pharma Co., Ltd. | Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5762922A (en) * | 1994-01-31 | 1998-06-09 | Ludwig Institute For Cancer Research | Antioxidants and intracellular gluthathione raising agents for therapeutic treatments |
| WO1995022342A1 (en) * | 1994-02-22 | 1995-08-24 | The Syntex-Synergen Neuroscience Joint Venture | Pharmaceutical formulations of ciliary neurotrophic factor |
| AU4149400A (en) | 2000-04-19 | 2001-10-30 | Neurotech Co Ltd | Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
-
2003
- 2003-01-20 KR KR10-2003-0003765A patent/KR100522188B1/ko not_active Expired - Fee Related
-
2004
- 2004-01-20 EP EP04703527A patent/EP1592429A4/en not_active Withdrawn
- 2004-01-20 WO PCT/KR2004/000119 patent/WO2004064844A1/en not_active Ceased
- 2004-01-20 CN CNA2004800024852A patent/CN1738627A/zh active Pending
- 2004-01-20 US US10/542,936 patent/US7608585B2/en not_active Expired - Lifetime
- 2004-01-20 JP JP2006500641A patent/JP2006515370A/ja active Pending
- 2004-01-20 CA CA002518888A patent/CA2518888A1/en not_active Abandoned
- 2004-01-20 AU AU2004206187A patent/AU2004206187A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006515370A5 (enExample) | ||
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| Ko et al. | Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats | |
| US9975868B2 (en) | 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto | |
| JP2006528236A5 (enExample) | ||
| JP2007500757A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| JP2002532432A5 (enExample) | ||
| JP2010507686A5 (enExample) | ||
| WO2008096271A3 (en) | Neuroprotection in demyelinating diseases | |
| WO2006034373A3 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| BRPI0517227A (pt) | forma de dosagem oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, método de tratamento de uma doença ou condição | |
| JP2009538269A5 (enExample) | ||
| JP2004527551A5 (enExample) | ||
| JP2005504782A5 (enExample) | ||
| WO2015115582A1 (ja) | アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤 | |
| WO2003077869A3 (en) | Neuroprotective spirostenol pharmaceutical compositions | |
| BRPI0414347A (pt) | associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade | |
| WO2007123848A3 (en) | Therapeutic compositions containing modified class i slrp proteins | |
| WO2007125566A3 (en) | Use of probiotics in the prevention and treatment of allergic conjunctivitis | |
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| JP2005511582A5 (enExample) | ||
| JP2002535334A5 (enExample) | ||
| WO2007106862A3 (en) | The use of statins to stimulate neurogenesis |